Figure 1
Distribution of cytogenetic abnormalities. Therapy-related AML (n = 179, A) and de novo AML (n = 2363, B; MDS-related cytogenetic abnormalities according to Swerdlow et al1 ).
Distribution of cytogenetic abnormalities. Therapy-related AML (n = 179, A) and de novo AML (n = 2363, B; MDS-related cytogenetic abnormalities according to Swerdlow et al1 ).
